Abstract:
PROBLEM TO BE SOLVED: To provide microcapsules comprising an agglomeration of primary microcapsules, each individual primary microcapsule having a primary shell and the agglomeration being encapsulated by an outer shell, providing an aqueous mixture of a loading substance and a shell material.SOLUTION: Microcapsules may be prepared by providing an aqueous mixture of a loading substance and a shell material, adjusting pH, temperature, concentration and/or mixing speed to form primary shells of shell material around the loading substance and cooling the aqueous mixture until the primary shells agglomerate and an outer shell of shell material forms around the agglomeration. Such microcapsules are useful for storing a substance and for delivering the substance to a desired environment.
Abstract:
PROBLEM TO BE SOLVED: To provide a fenofibrate-containing composition which is equal in biological utilization to a conventional capsule preparation and which is effective in reducing the size of the conventional capsule preparation.SOLUTION: The fenofibrate-containing composition is obtained by adding a binder and a disintegrator in a total amount of 17-20 pts.wt. to a mixture comprising the following components: (a) 100 pts.wt. fenofibrate, (b) 3-4 pts.wt. solid surfactant, (c) 1-2 pts.wt. lactose, and (d) 1-2 pts.wt. magnesium stearate, wherein the fenofibrate and the solid surfactant are pulverized together.
Abstract:
The present invention relates to a method for preparing microcapsules by coacervation, and to the use of transglutaminase for cross-linking in complex coacervation. The present invention relates further to coacervation processes in general in which a material to be encapsulated is added to a solution comprising at least one colloid below the gelling temperature of the colloid. According to a method of the present invention, an emulsion or suspension of hydrophobic material is prepared after cooling a solution that includes hydrocolloids below the critical gelling temperature of a coacervate phase.
Abstract:
PROBLEM TO BE SOLVED: To provide a pharmaceutical composition including a mycophenolate salt which is suitable for releasing mycophenolate at the upper part of the enteric canal. SOLUTION: The coating comprising cellulose acetate phthalate and cellulose trimellitate or methacrylic acid copolymer including at least 40% of methacrylic acid or the coating including hydroxypropylmethyl cellulose phthalate are used to prepare a coating agent. Medicinally acceptable sodium mycophenolate salt is allowed to be included in the coating agent to prepare the medicinal composition. COPYRIGHT: (C)2006,JPO&NCIPI
Abstract:
An aromatic heterocyclic compound has the formula wherein R1 represents (i) -CH3, (ii) -CH2OH or (iii) wherein R3 represents hydrogen, -OR4 wherein R4 represents hydrogen, alkyl having 1-20 carbon atoms, mono- or polyhydroxyalkyl or R3 represents wherein r'and r'' represent hydrogen or lower alkyl, R2 represents hydrogen or -CH3 and Ar represents (A) (B) wherein Z is O or S, (C) wherein R5 is lower alkyl or (D) wherein R6 is hydrogen or alkyl having 1-10 carbon atoms and R7 represents alkyl having 4-12 carbon atoms or cycloalkyl, Y is CH and X represents oxygen or sulfur, with the proviso that (i) when Y is CH and X is oxygen or sulfur Ar is other than C wherein R5 is CH3 and (ii) when Y is CH and X represents sulfur Ar is other than A. The compound is useful in the treatment of dermatologic ailments linked to a keratinization disorder.
Abstract:
A pharmaceutical composition, comprising a thiazolidinedione, such as Compound (I), metformin hydrochloride and a pharmaceutically acceptable carrier, wherein the thiazolidinedione and metformin hydrochloride are each dispersed within its own pharmaceutically acceptable carrier in the pharmaceutical composition and the use of such a composition in medicine.